Triple knockdown of CDC37, HSP90-alpha and HSP90-beta diminishes extracellular vesicles-driven malignancy events and macrophage M2 polarization in oral cancer

Kisho Ono, Chiharu Sogawa, Hotaka Kawai, Manh Tien Tran, Eman A. Taha, Yanyin Lu, May Wathone Oo, Yuka Okusha, Hirohiko Okamura, Soichiro Ibaragi, Masaharu Takigawa, Ken-Ichi Kozaki, Hitoshi Nagatsuka, Akira Sasaki, Kuniaki Okamoto, Stuart K. Calderwood & Takanori Eguchi

To cite this article: Kisho Ono, Chiharu Sogawa, Hotaka Kawai, Manh Tien Tran, Eman A. Taha, Yanyin Lu, May Wathone Oo, Yuka Okusha, Hirohiko Okamura, Soichiro Ibaragi, Masaharu Takigawa, Ken-Ichi Kozaki, Hitoshi Nagatsuka, Akira Sasaki, Kuniaki Okamoto, Stuart K. Calderwood & Takanori Eguchi (2020) Triple knockdown of CDC37, HSP90-alpha and HSP90-beta diminishes extracellular vesicles-driven malignancy events and macrophage M2 polarization in oral cancer, Journal of Extracellular Vesicles, 9:1, 1769373, DOI: 10.1080/20013078.2020.1769373

To link to this article: https://doi.org/10.1080/20013078.2020.1769373
Triple knockdown of CDC37, HSP90-alpha and HSP90-beta diminishes extracellular vesicles-driven malignancy events and macrophage M2 polarization in oral cancer

Kisho Ono, Chiharu Sogawa, Hotaka Kaiwai, Manh Tien Tran, Eman A. Taha, Yanyin Lu, May Wathone Oo, Yuka Okusha, Hirohiko Okamura, Soichiro Ibaragi, Masaharu Takigawa, Ken-Ichi Kozaki, Hitosshi Nagatsu, Akira Sasaki, Kuniaki Okamoto, Stuart K. Calderwood and Takanori Eguchi

*Department of Dental Pharmacology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan; †Department of Oral and Maxillofacial Surgery, Okayama University Hospital, Okayama, Japan; ‡Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama, Japan; ‡Department of Oral Morphology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan; *Advanced Research Center for Oral and Craniofacial Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan; ‡Department of Oral and Maxillofacial Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan; †Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

Evidence has been accumulating to indicate that extracellular vesicles (EVs), including exosomes, released by cancer cells can foster tumour progression. The molecular chaperones – CDC37, HSP90α and HSP90β play key roles in cancer progression including epithelial-mesenchymal transition (EMT), although their contribution to EVs-mediated cell–cell communication in tumour microenvironment has not been thoroughly examined. Here we show that triple depletion of the chaperone trio attenuates numerous cancer malignancy events exerted through EV release. Metastatic oral cancer-derived EVs (MEV) were enriched with HSP90α HSP90β and cancer-initiating cell marker CD326/EpCAM. Depletion of these chaperones individually induced compensatory increases in the other chaperones, whereas triple siRNA targeting of these molecules markedly diminished the levels of the chaperone trio and attenuated EMT. MEV were potent agents in initiating EMT in normal epithelial cells, a process that was attenuated by the triple chaperone depletion. The migration, invasion, and in vitro tumour initiation of oral cancer cells were significantly promoted by MEV, while triple depletion of CDC37/HSP90α/β reversed these MEV-driven malignancy events. In metastatic oral cancer patient-derived tumours, HSP90β was significantly accumulated in infiltrating tumour-associated macrophages (TAM) as compared to lower grade oral cancer cases. HSP90α-enriched MEV-induced TAM polarization to an M2 phenotype, a transition known to support cancer progression, whereas the triple chaperone depletion attenuated this effect. Mechanistically, the triple chaperone depletion in metastatic oral cancer cells effectively reduced MEV transmission into macrophages. Hence, siRNA-mediated knockdown of the chaperone trio (CDC37/HSP90α/HSP90β) could potentially be a novel therapeutic strategy to attenuate several EV-driven malignancy events in the tumour microenvironment.

**Abbreviations:** CDC37: cell division control 37; EMT: epithelial-mesenchymal transition; EV: extracellular vesicles; HNSCC: head and neck squamous cell carcinoma; HSP90: heat shock protein 90; TAM: tumour-associated macrophage

**Introduction**

Extracellular vesicles (EVs) are extracellular nano-particles surrounded by lipid membranes containing a variety of molecular cargos such as proteins, small and long RNA, DNA molecules, glycan and metabolites that are secreted by cells [1,2]. Major EV subtypes are endosome-originated exosomes and plasma membrane-derived ectosomes (aka microvesicles or microparticles) while additional types of EVs consisting of large oncosomes (1–10 μm), matrix vesicles, migrasomes, exophores (~4 μm), exomeres (~35 nm) and bacterial outer membrane vesicles have been reported [3,4]. EVs can play roles in discarding redundant intracellular materials while also mediating cell–cell communication when their cargos reached recipient cells/organs [5,6]. These vesicles also play pivotal roles in influencing the local tumour microenvironment, enter body...
HSP90 is a chaperone protein involved in the folding and assembly of proteins [8,12,13]. It is essential for the proper function of many proteins by preventing their aggregation and facilitating their correct folding, transport, and degradation. The HSP90 family includes four members: HSP90α, HSP90β, HSP90α-1, and HSP90β-1. These paralogs are involved in diverse cellular functions such as protein folding, membrane transport, and intracellular signaling [8,12,13].

HSP90 has been implicated in various cellular processes, including protein folding, transport, and degradation [8,12,13]. It plays a crucial role in the folding and assembly of several important client proteins, including those involved in cell adhesion, migration, and invasion [8,12,13]. In this regard, HSP90 has been suggested to function as a molecular chaperone in the cell, facilitating the proper folding and maturation of client proteins [8,12,13].

HSP90 has also been shown to be involved in cell adhesion, migration, and invasion [8,12,13]. In this regard, HSP90 has been suggested to function as a molecular chaperone in the cell, facilitating the proper folding and maturation of client proteins [8,12,13].

The HSP90 family consists of four members, including the proteotoxic stress-inducible HSP90α encoded by HSP90AA1, the constitutively expressed HSP90β encoded by HSP90AB1, the mitochondrially localized TRAP1, and an ER-resident paralog Gp96 (aka Grp94 or endoplasmic reticulum stress-associated protein) [12,17]. Notably, HSP90α is often overexpressed in cancer cells and can be secreted to the extracellular space as a soluble protein or as a cargo protein of EVs [10,12,18]. Recently, the EV-proteome analysis of oral cancer cells has revealed abundant secretion of EVs enriched with HSP90 from high-metastatic oral cancer cells [12].

Epithelial-mesenchymal transition (EMT) is a biological event in tumour cells that involves a change in cell morphology, cell-matrix adhesion, and cell-cell adhesion [14,18]. The process is characterized by the loss of epithelial cell markers and the acquisition of mesenchymal markers, leading to increased cell motility, invasion, and migration [14,18]. EMT is associated with the downregulation of epithelial markers and the upregulation of mesenchymal markers [14,18].

In the present study, we aimed to examine: (i) if high-metastatic oral cancer-derived EVs could promote cancer malignancy properties such as EMT, enhanced migration, increased invasion, tumour initiation, and macrophage M2 polarization, (ii) if triple depletion of the chaperone trio – CDC37, HSP90α and HSP90β – could lessen the effects of EVs on tumour progression. We also aimed to investigate (iii) HSP90 expression and distribution in tumours, their stroma and in TAM in different malignancy grades of oral cancer, to elucidate potential roles of HSP90-EVs in the tumour microenvironment.

Materials and methods

Cell culture

HSC-3, HSC-3-M3, Ca9-22, HO-1-u-1, SAS, HSC-2, HSC-4 and THP-1 were obtained from JCRB Cell Bank and maintained in DMEM containing 10% FBS. An immortalized oral mucosa epithelial cell line RT7 was provided by Dr Nobuyuki Kamata at Hiroshima University and maintained in KGM-gold (Lonza). For EV preparation, cells were cultured in serum-free DMEM. THP-1 was maintained in RPMI-1640 with 10% FBS and for macrophage-like differentiation, stimulated with 200 nM of phorbol 12-myristate 13-acetate (PMA) for 24 h.
**siRNA transfection**

We designed siRNA sequences targeting mRNA of CDC37, HSP90AA1 or HSP90AB1 (Supplementary Table 1) [10,12]. For targeting each mRNA, a mixture of two types of siRNA duplex was used. The control non-targeting siRNA was purchased from Nippon Gene. siRNA was transfected as described previously [10]. Briefly, cells were pre-cultured in DMEM containing 10% FBS for 1 day or until 60–80% confluence and then transfected with siRNA at a final concentration of 5 nM using Lipofectamine RNAi MAX (ThermoFisher). The medium was replaced with serum-free one at 24 h post-transfection. Cells were then cultured for 48 h before EV preparation, ATP-based cell viability assay, and lactate dehydrogenase release (LDH) assay. For Gluc assay, cell culture supernatants were collected at 6, 24 and 48 h post-medium replacement. At the same time points, cells were detached using Trypsin/EDTA and stained with Trypan Blue for cell counting. The number of Trypan Blue-negative and -positive cells were counted.

**EV and EV-free fractions**

EV fraction and soluble fraction were prepared from serum-free culture supernatants at 48 h post-medium replacement using a modified polymer-based precipitation method as described [10,12]. Simultaneously, whole cell lysates were prepared as described below. Briefly, cell culture supernatant was centrifuged at 2,000 × g for 30 min at 4°C. The supernatant was centrifuged at 10,000 × g for 30 min at 4°C. The supernatants were filtered with a 0.2-µm pore filter in a few experiments, as shown in supplemental items. The pass-through was concentrated using an ultrafiltration device for MW.100 k to separate an EV fraction and soluble EV-free fraction. The concentrate was applied to polymers of Total Exosome Isolation (ThermoFisher). The pass-through was concentrated using an ultrafiltration device for MW.10 k and used as EV-free conditioned media. The EV fractions were suspended in 100–200 µL PBS (−). For protein assay, 10 µL of 10× RIPA buffer and 100× a protease inhibitor cocktail (Sigma) were added to the 100 µL of the EV fraction and incubated on ice for 15 min. Protein concentration was analysed using micro BCA protein assay (ThermoFisher).

**Whole cell lysate**

The whole cell lysate (WCL) was prepared as described previously [5,10]. Briefly, cells cultured in a 6-cm dish were lysed in 150–200 µL/dish of a RIPA buffer (1% NP-40, 0.1% SDS, and 0.5% deoxycholate, and EDTA-free protease inhibitor cocktail in PBS) and collected by using a cell scraper. Cells were further lysed by a 25-gauge syringes for 10 strokes and then incubated for 30 min on ice. The lysate was centrifuged at 12,000 × g for 20 min at 4°C and the supernatant was used as a WCL. Protein concentration of the WCL was analysed using micro BCA protein assay (ThermoFisher).

**Western blotting**

Western blotting was performed as described [10,13,43]. The same protein amounts of WCL were subjected to SDS-PAGE, followed by transfer to a PVDF membrane using wet- and semi-dry methods where appropriate. The membranes were blocked in 5% skim milk in Tris-buffered saline containing 0.05% Tween 20 for 60 min, incubated with primary antibodies, and then incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies. For CD63, blocking was performed in 10% overnight and the primary antibody was reacted for 2 days. Blots were visualized with ECL substrate. We used antibodies against CD9 (MEX001-3, Medical and Biological Laboratories), CD63 (EXOAB-CD63A-1, System Biosciences), HSP90α (GTX109753, GeneTex), HSP90β (GTX101448, GeneTex), MMP9 (ab38898, Abcam) and HRP-conjugated anti-β-actin antibody (clone 2F3, Fujifilm/Wako) as optimized previously [5,8,10,12,23,44]. Antibodies against CD326 (VU1D9), CDC37 (D11A3), E-cadherin (24E10), β-catenin (D10A8), Vimentin (D21H3), Snail (C15D3), Claudin-1 (D5H1D) and COX-4 (3E11) were purchased from Cell Signaling Technology.

We loaded the same protein amount per lane in each Western blotting experiment. To obtain relative expression levels, relative band intensities were measured in the same membrane using ImageJ. The raw values were converted into relative values as control = 1.0. For normalization, relative levels of the protein of interest per loading control were calculated.

**Transmission electron microscopy (TEM)**

TEM and particle diameter distribution analysis were carried out as described previously [10,12]. Briefly, a 400-mesh copper grid coated with formvar/carbon films was hydrophilically treated. The EV suspension (5–10 µL) was placed on Parafilm, and the grid was floated on the EV liquid and left for 15 min. The sample was negatively stained with 2% uranyl acetate.
solution for 2 min. EVs on the grid were visualized with 20,000 times magnification with an H-7650 transmission electron microscope (Hitachi, Tokyo, Japan).

**Particle size distribution**
A part of EV fraction was diluted within PBS (−) to volume up to 40 μL and then analysed using Zetasizer nano ZSP (Malvern Panalytical, Malvern, UK) in a range of 0.3–10,000 nm-diameters, as described [10,12]. Alternatively, a part of EV fraction was mixed with PBS (−) to volume up to 250 µL and then particle diameters of EV fractions were analysed using ELS-8000 (Otsuka Electronics, Hirakata, Japan) between 30 and 1000 nano-diameters, as described [8].

**Fluorescent ceramide-labelled EV transmission**
As described [8,45,46], 20 μg of EV fraction was incubated with 10 μM BODIPY TR Ceramide (ThermoFisher) for 20 min at 37°C. Excessive dye was removed using Exosome Spin Columns (MW. 3000) (ThermoFisher). The labelled EVs were added to the culture medium of HSC-3 cells in 96-well plates at 25 μg/mL. Cells were fixed with 4% paraformaldehyde in PBS for 10 min and permeabilized with 0.5% Tween-20 in PBS for 5 min. Cells were incubated with ActinGreen488 (ThermoFisher) for 30 min and with DAPI for 5 min. Fluorescence images of random four fields were taken using a Floid® Imaging Station (ThermoFisher) and fluorescence-positive cells in each field were counted.

**EV reporters**
The lentiviral reporter constructs of CSCW-palmitoylation signal-tandem dimer Tomato (palmT), CSCW-palmitoylation signal-EGFP (palmG) [47] and CSCW-Gaussia luciferase acceptor-PDGFR transmembrane-IRES-GFP (mbGluc) [48] were kindly gifted from Dr Charles P. Lai. For virus production, HEK293T cells at 70–80% confluence were transfected with PalmT or PalmG constructs, psPAX2 packaging plasmid and pMD2.G envelope plasmid using PEI max (Polysciences). HSC-3, HSC-3-M3 or THP-1 cells were infected by using spinfection method with the viral solution. Infected/transduced stable cells were selected using puromycin. Isolation of single clones was carried out by limiting dilution method. We established palmtTomato-expressed HSC-3-M3 cells (designated HSC3M3/palmtT), palmGFP-expressed HSC-3-M3 cells (designated HSC3M3/palmG), palmGFP-expressed HSC-3 cells (designated HSC3/palmG) and palmGFP-expressed THP-1 cells (designated THP1/palmG) [46].

**Luciferase assay**
Gaussia luciferase activities were quantified using a Gaussia luciferase glow kit (Pierce). Culture supernatants of cells transfected with siRNA were collected at 6, 24 and 48 h after the replacement of media. Cell culture supernatant (10 or 20 µL) was mixed with 50 µL of coelenterazine working solution in a white 96-well plate. Luminescence was measured in a plate reader Gemini XP SOK (Molecular Devices).

**Confocal laser-scanning microscopy**
CLSM was carried out as described previously [5,8,49]. Briefly, recipient cells were seeded on a type I collagen-coated coverslip in a 24-well plate at a density of 1 × 10⁴ cells per well and cultured for 24 h in a serum-containing culture media. EVs (HSC3 M3/palmT-EV; 5 μg/mL) or PBS were added to the culture media. After the incubation for 24 h, cells were fixed with 4% paraformaldehyde in PBS for 10 min. Fluorescence images were taken using a CLSM system (LSM 780 META; Carl Zeiss).

**Reporter vesicle transmission**
As recipients, HSC3/palmG cells or THP1/palmG cells treated with PMA for 24 h were seeded in a 96-well plate at a concentration of 1 × 10⁴ cells/well and cultured for 24 h in a serum-containing culture media. EV fractions (2.5 and 25 μg/mL) or PBS were added to the culture media. The transmission of the palmT-EVs was monitored every 1 h for 8 h in ArrayScan High Content Screening (HCS) System (ThermoFisher). The fluorescence intensity of each cell was determined using a filter set (485/594) for (GFP/Tomato). The fluorescence intensity values less than 85 and 60 were defined as the background values in recipient HSC3/ palmG and macrophage-like THP1/palmG cells, respectively, and subtracted from the raw values. The fluorescence-positive cells were counted in one field (2,632 μm²). The transmission rate was calculated as a percent of exogenous palmT-positive cells per palmG-positive recipient cells with a fluorescence intensity 35 or more.

**Cell viability**
Cell viability was measured as described previously [50–52]. ATP content was quantified using a CellTiterGlo (CTG) Luminescent Cell Viability Assay (Promega Co., Madison, WI). Cells were detached using Trypsin/EDTA and suspended with
150 µL of CTG solution and incubated for 10 min at 37°C. Luminescent measurements were done on the plate reader Gemini XP SOK (Molecular Devices).

**Lactate dehydrogenase release assay**

Cytotoxicity was measured using the index of lactate dehydrogenase (LDH) release from cells, as described previously [10]. The LDH activity was measured using the LDH cytotoxicity assay kit (Nacalai Tesque, Kyoto, Japan) according to the manufacturer’s instructions. The culture supernatants of cells transfected with siRNA were collected at 48 h after the replacement of media (72 h after siRNA transfection). The collected supernatants were transferred to another 96-well plate and incubated with substrate solution at RT for 20 min. The cells were lysed with cell lysis buffer, then incubated with substrate solution at RT for 20 min. The stop solution was added and absorbance (490 nm) was measured. Each absorbance was converted into a relative value to the control. For normalization, the relative level of LDH release per cell number was calculated.

**Morphological analysis of EMT**

Cellular EMT morphology was analysed as described previously [8,10]. Briefly, HSC-3-M3 cells were transfected with siRNAs. Then, culture media were replaced with serum-free ones. Cells were further cultured for 48 h. Then photomicrographs of random four fields were taken using a Floid® Imaging Station (ThermoFisher). Spindle-shaped cells were defined as the cells with more than two-fold length/width ratio.

RT7 cells were cultured in KGM-2 in 96-well plates and EV (50 μg/mL) or PBS were added to the culture media. Spindle-shaped cells longer than 80 μm in random three fields were counted using ImageJ at 48 h post-EV addition.

**Immunocytochemistry**

THP-1 cells were treated with PMA for 24 h for macrophage-like differentiation. EVs were added to culture media of the differentiated THP-1 in 96-well plates at 25 µg/mL. Cells were further cultured for 48 h and fixed with 4% paraformaldehyde in PBS for 10 min and permeabilized with 0.5% Tween-20 in PBS for 5 min. Immunocytochemistry was carried out as described previously [5,49]. The fixed cells were blocked in normal goat serum solution for 30 min, incubated with rabbit anti-CD206 (ab64693, Abcam) and mouse anti-CD68 IgG (M0814, Dako/Agilent) in PBS, and incubated with anti-rabbit IgG AlexaFluor488 and anti-mouse IgG AlexaFluor568. Cells were incubated with DAPI. Fluorescence images of random nine fields were taken using Floid* Imaging Station. To define CD206 or CD68 positivity, the fluorescence intensity of the cells without the primary antibody was subtracted as background.

**Wound healing assay**

Confluent HSC-3 cells in 48-well plates were wounded by scratching with pipette tips. EVs (50 µg/mL) or PBS were added to culture media. Images were captured immediately and subsequently at 8 h using Floid* Imaging Station. The percentage of the area closed in 8 h was measured using Image J.

**Migration assay and invasion assay**

Migration/invasion assays were carried out as described previously [5,51]. Briefly, uncoated and Matrigel-coated culture systems were used for in vitro migration and invasion assays, respectively. HSC-3 cells (25 k cells) in serum-free DMEM were mixed with EVs (10 µg/mL) or PBS and immediately seeded to an upper chamber of Transwell® 24-well (Corning). Cells migrated/invaded to the lower surface of filters were fixed, stained using Diff-Quick, and counted at 33 h post-seeding period.

**Tumoroid formation**

Tumoroid (or tumorsphere) formation assay was performed as described [13,45,50,51]. Briefly, HSC-3 cells were cultured with EVs (50 µg/mL) or PBS in serum-free DMEM in 96-well NanoCulture Plates (Medical and Biological Laboratories) for 2 days. Lox-1 probe (Medical and Biological Laboratories) was added to culture media at 2 µM and then cells/tumorspheres were cultured for 24 h. Tumorspheres with red fluorescence were measured using the ArrayScan HCS System (ThermoFisher). The fluorescence intensity was determined using a filter set for TRITC. For counting spheroids, the size of each tumorsphere (spheroid) in the entire cell population was measured. The size of the top 300 tumorspheres from three wells in each experimental group was counted and dot-plotted. Fluorescent areas greater than 300 µm² were counted in each well and calculated the average number of spheroids in three wells. A single well of a 96-well plate was sectionized to 9 fields, and the area of 1 field is 2,632 µm².
Patient-derived samples

Sixteen oral squamous cell carcinoma tissues (stage I: n = 8, stage IV: n = 8) resected at Okayama University Hospital Oral Surgery were examined. The study was approved by the Okayama University Human Ethics Committee (Approval number: 1608–018) and informed consent was obtained from all patients.

Immunohistochemistry

IHC was carried out as described previously [53,54]. Paraffin blocks of specimens were cut at 3-µm thickness. The sections were deparaffinized and then autoclaved in a 0.2% citrate buffer for 15 min. Sections were incubated with 3% hydrogen peroxide for 30 min. Sections were treated with 10% normal goat serum for 30 min, incubated with anti-HSP90α (GTX109753, GeneTex) and anti-HSP90β (GTX101448, GeneTex) antibodies at 4°C overnight, and visualized with the avidin-biotin complex method (PK4001, Vector Laboratories). To rate HSP90-positive cancer cells, five areas were randomly chosen in each tumour specimen at high magnification (×200) and HSP90α or HSP90β-positive cancer cells were counted. To rate HSP90-positive stromal cells, five areas were randomly chosen in each specimen and HSP90α or HSP90β-positive stromal cells per 100 mm² stromal area were counted. The criteria of positive cells were cells that exhibited DAB colouration determined by two pathologists.

Co-expression correlation

The data set of head and neck squamous cell carcinoma (HNSCC) with 523 patient-derived 523 samples (TCGA, Pan-Cancer Atlas) was analysed using cBioPortal.

Statistical analysis

Statistical significance was calculated using GraphPad Prism and Microsoft Excel. The difference between the two sets of data was examined by unpaired student’s t-test. P < 0.05 was considered to indicate statistical significance. Data were expressed as means±SD unless otherwise specified. The size of tumorspheres was statistically analysed using ANOVA Tukey’s multiple comparisons test and expressed as mean±SD.

Results

Metastatic oral cancer-derived EVs enriched with HSP90 promote cancer cell migration

We asked firstly whether HSP90α and HSP90β were secreted in EVs released by seven oral squamous cell carcinoma cell lines and one oral epithelial cell line, known as RT7. HSP90α was found in EVs secreted by the seven cell lines (Ca9-22, HO-1-u-1, SAS, HSC-2, HSC-3, HSC-4 and HSC-3-M3) and by RT7 (Fig. S1). By contrast, HSP90β was markedly found in EVs secreted by the highly metastatic HSC-3-M3, but not detected in EVs secreted by the other seven cell lines. High-metastatic HSC-3-M3-derived EVs (M3-EV) contained significantly higher levels of HSP90α and HSP90β compared to HSC-3-derived EVs (HSC3-EV) (Figure 1a,b; Fig. S2). Additionally, M3-EV contained a higher level of CD326 compared to HSC3-EV. Moreover, M3-EV tended to contain a higher level of CD63 compared to HSC3-EV. Both HSC3-EV and M3-EV possessed cup-like shapes (Figure 1c, Fig. S3), although M3-EV (average 141.8 nm) tended to be larger than HSC3-EV (average 119.2 nm) (Figure 1d–g; Fig. S4). The main populations of HSC3-EV and M3-EV were between 50 and 200 nm diameters.

We next examined the co-expression correlation between the HSP90AA1 gene, which encodes HSP90α and the HSP90AB1 gene encoding HSP90β, among 523 tumour samples derived from 523 HNSCC patients registered in the cancer genome atlas. A high-level co-expression correlation was found between HSP90AA1 and HSP90AB1 with Spearman’s correlation score 0.52 (p = 2.59e–37), Pearson’s correlation score 0.50 (p = 2.71e–34) and a regression line (y = 0.44x±8.39) (Figure 1h). The positive correlation of co-expression between HSP90AA1 and HSP90AB1 may be consistent with the co-expression of HSP90α and HSP90β observed in M3-EV derived from high-metastatic oral cancer in Figure 1a,b. To query the pro-migratory potential of oral cancer-derived HSC3-EV and M3-EV, we next performed a scratch wound-healing assay. Treatment with either M3-EV or HSC3-EV promoted significant levels of migration of HSC-3 cells, effectively closing the scratched wound, while M3-EV was a more potent pro-migratory agent than HSC3-EV (Figure 1i,j).

These data indicate that metastatic oral cancer-derived EVs are enriched with HSP90α and HSP90β and promote cancer cell migration.

siRNA-mediated knockdown of CDC37/HSP90α/ HSP90β diminishes the EMT phenotype in metastatic oral cancer cells

We have shown that M3-EV tended to be enriched with HSP90α and HSP90β [12]. We also reported that the double-knockdown of HSP90α and HSP90β significantly reduced the survival of metastatic oral cancer cells, although single knockdown of each HSP90 was
ineffective in this regard [12]. Next, we examined whether the knockdown of CDC37/HSP90α/β could alter the survival of metastatic oral cancer cells. Single knockdown of each chaperone did not alter the survival of HSC-3-M3 cells, while the triple knockdown of CDC37/HSP90α/β reduced the survival of the metastatic oral cancer cells (Fig. S5). It was thus suggested that triple targeting of the molecular chaperone trio could be antitumorigenic and potentially damage targeted cells.

Increases in cellular migration and motility have been associated with a phenotypic change of the cells.
from epithelial to mesenchymal properties – EMT [26]. CDC37, a key cochaperone for both paralogs of HSP90, is essential in chaperoning the EMT-promoting kinase signals in cancer cells [28,44]. Moreover, knockdown of CDC37 diminished EV protein release and the EMT properties of prostate cancer cells [10,55]. We therefore next asked whether CDC37 and HSP90α/β could act cooperatively in the EMT process. This experiment involved targeting of CDC37, HSP90α and/or HSP90β and determining the levels of EMT markers in HSC-3-M3. We first confirmed that individual siRNA aimed at either HSP90α, HSP90β or CDC37 could successfully silence the translated protein levels of their mRNA targets in HSC-3-M3 (Figure 2a, top to third raw blot; Fig. S6). However, siRNA-mediated depletion of HSP90α triggered simultaneous increases in HSP90β, while depletion of HSP90β triggered simultaneous increases in HSP90α as well, suggesting a compensatory response within the CDC37/HSP90 system. This observed compensatory response therefore rationalized the use of double and triple depletion of CDC37, HSP90α and HSP90β in this study to effectively neutralize the HSP90/CDC37 chaperone system. Additionally, the siRNA-mediated silencing of HSP90β reduced the level of CDC37, and vice versa, the silencing of CDC37 led to reductions in both CDC37 and HSP90β. Nevertheless, double and triple targeting of CDC37, HSP90α and/or HSP90β successfully diminished the levels of each of the chaperone trio in the metastatic oral cancer cells (Figure 2a, top to third raw blot; Fig. S6).

Next, we asked whether EMT properties could be altered by the chaperone depletion. The concentration of the most prominent mesenchymal marker vimentin was reduced by either a combination of double depletion or most profoundly by the triple knockdown of the chaperone trio (Figure 2a–c, Fig. S7). The epithelial marker E-cadherin was increased by double depletion of HSP90α/β and by triple chaperone depletion (Figure 2a–c). The most prominent alteration was observed in the levels of claudin-1, an epithelial tight junction component. Claudin-1 was profoundly elevated by either single depletion of CDC37 alone or double/triple depletion of CDC37/HSP90α/β (Figure 2a–c), suggesting that silencing CDC37 could lead to the claudin-1-positive epithelial phenotype.

![Figure 2](image_url)

**Figure 2.** The siRNA-mediated knockdown of CDC37/HSP90α/HSP90β diminishes the EMT phenotype in metastatic oral cancer cells. (a) Representative Western blotting showing HSP90α, HSP90β, CDC37, and EMT markers. HSC-3-M3 cells were transfected with siRNAs targeting CDC37, HSP90α and/or HSP90β or non-targeting siRNA (si-Ctrl) for 48 h. COX4, loading control. Similar data were obtained from two independent experiments. (b–e) Anti-EMT effect of triple chaperone knockdown. HSC-3-M3 cells were transfected with siRNAs targeting CDC37/HSP90α/HSP90β or si-Ctrl. Medium was replaced with serum-free one at 24 h post-transfection. Cells were further cultured 48 h prior to protein sampling and photo taking. (b) Western blotting showing EMT markers. β-actin, loading control. Similar data were obtained from four independent experiments. (c) Alteration of EMT markers. The band intensities of Western blotting were quantified. (d,e) Morphological analysis of EMT. (d) Representative photomicrographs of HSC-3-M3 cells transfected with siRNA. Arrowheads indicate spindle-shaped cells. Scale bars, 100 μm. Similar data were obtained from three independent experiments. (e) Rates of spindle-shaped cells. Spindle shaped cells were defined as the cells with more than two-fold length/width ratio. n = 4 random fields.
CD326 aka EpCAM has been shown as a type of epithelial marker as well as tumour-initiating cell marker [13,56,57]. In our study, CD326 tended to be increased by the triple knockdown of the chaperones, consistently with other epithelial markers (Figure 2b,c). Thus, triple depletion of CDC37/HSP90α/β reduced the EMT properties of metastatic oral cancer cells more effectively than both single and double chaperone depletion.

We next examined morphological changes in the metastatic oral cancer cells upon chaperone silencing. To evaluate morphological changes coupled with EV release, the culture medium was replaced with serum-free one at 24 h post-transfection and cells were further cultured for 48 h before photo taking and EV sampling. Cell viabilities were not much altered in this protocol between the control and triple knockdown (Fig. S8). The most noticeable difference was observed between control siRNA-transfected and triple-silenced cells. A spindle-like shaped morphology, one of the principal characteristics of EMT, was observed in the control cells, whereas cells significantly reverted to a more typically epithelial morphology upon triple chaperone depletion (Figure 2d,e; Fig. S8).

These findings indicate that the siRNA-mediated triple chaperone knockdown of CDC37, HSP90α and HSP90β could diminish the EMT phenotype in metastatic oral cancer cells.

**Triple chaperone knockdown reduced HSP90α, HSP90β and tetraspanins in metastatic EVs**

It has been shown that tetraspanins such as CD9 and CD63 play crucial roles in intercellular communication [58–60]. Besides, we recently reported that a single knockdown of CDC37 reduced EV-associated CD9 release from prostate cancer cells [10]. We therefore hypothesized that molecular chaperones could regulate the stability and release of tetraspanins with EVs. We queried whether siRNA-mediated triple depletion of CDC37/HSP90α/β could alter the incorporation of HSP90 and tetraspanins (CD9 and CD63) from cancer cells to EVs. We here used the same protocol of cell culture used in Figure 2d,e and Fig. S8. We observed depletion of HSP90α levels in cell lysates, EV fractions and the EV-free soluble culture supernatant by the triple chaperone depletion (si-Ctrl vs si-CDC37/HSP90α/β) (Figure 3a–c, Fig. S9).

We recently reported that cell stress triggered stressosome release including extracellular HSP90α and damaged membrane vesicles [10]. It is conceivable that siRNA transfection could also lead to membrane damage and the release of cytosolic proteins and intracellular protein degradation of stressome components. Hereafter, we define EVs derived from control siRNA-transfected HSC-3-M3 cells as MEV, and EVs derived from triple siRNA (CDC37/HSP90α/β) transfected HSC-3-M3 cells as T-MEV. Next, we compare the different properties of MEV and T-MEV. The morphologies and sizes of EVs were similar between MEVs and T-MEVs. MEVs and T-MEVs had cup-like morphologies (Figure 3f,g; Fig. S10). The main populations of MEV and T-MEV sized between 50 and 400 nm with a peak at approx. 185 nm, while minor smaller particles (20–30 nm) were detected (Figure 3h, i; Fig. S10).

These data suggest that the chaperone trio CDC37/HSP90α/β could be crucial in intracellular proteostasis and extracellular release of EV proteins, including tetraspanins and thereby triple chaperone knockdown altered proteome signature including CD9 and CD63 in the cells and EVs.
We recently showed that cell stress triggers the release of stressome including EVs, HSP90 and LDH, a marker of cell membrane damage, from cancer cells [10]. CDC37 was also induced intracellularly by cell stress [10]. We therefore hypothesize that the chaperone trio is involved in membrane damage-related release of EVs.

Moreover, a previous study reported that *Gaussia princeps*-derived luciferase (Gluc) fused with PDGFR transmembrane domain was anchored to the lipid-bilayered membrane and then released from producer cells [48]. To quantify the release of EVs, we established a stable cell line designated as HSC3 M3/mbGluc that produce membrane-bound Gluc (mbGluc) (Figure 4a,b). The morphology of vesicles released by the HSC3 M3/mbGluc cells was cup-shaped and sized between 50 and 200 nm (Figure 4c, Fig. S11). Gluc activity was detectable and quantitative in the culture supernatant of HSCM3/mbGluc cells (Figure 4d,e). mbGluc was released from HSC-3-M3/mbGluc cells into culture media in a time-dependent manner at 6, 24 and 48 h culture period (Figure 4f). Triple targeting of CDC37/HSP90α/β lowered the release of mbGluc at 6–24 h post-medium replacement (Figure 4f). These data indicate that the chaperone trio is involved in EV release.
The total protein concentrations of the EV fractions were not different between the triple knockdown versus the control, as shown in Figure 3e. However, mbGluc release was delayed by the triple knockdown. Therefore, it is conceivable that EVs containing mbGluc, HSP90, CD9 and CD63 were reduced by the triple knockdown, while other components must be increased instead.

We also examined whether cellular growth, viability, and damage were altered by the triple knockdown of CDC37/HSP90α/β in HSC3 M3/mbGluc cells. Cellular growth and viability were not altered between the triple siRNA-transfected cells and control cells (Fig. S12a–d), while LDH release was inhibited by the triple knockdown of CDC37/HSP90α/β (Fig. S12e–g).

These data indicated that triple knockdown of CDC37/HSP90α/β could lower the release of EVs from cancer cells.

**Figure 4.** Triple knockdown of CDC37/HSP90α/β inhibited the release of membrane-bound *Gaussia* luciferase (mbGluc) reporter. The expression construct of mbGluc fused with the PDGFR transmembrane domain was stably transfected to HSC-3-M3 cells. GFP was co-expressed by an internal ribosomal entry sequence (IRES) for labelling the donor cells designated as HSC3M3/mbGluc. (a) Schemes showing a concept of Gluc-labelled EVs. (b) Representative images of HSC3M3/mbGluc cells. Left, an image of GFP-expressed HSC3M3/mbGluc cells. Right, a bright-field image. Scale bars, 100 μm. (c) A representative TEM images of mbGluc-MEV. Scale bars, 200 nm. (d, e) Establishment of mbGluc quantification. (d) Relative Gluc activities of 20 μL culture media of HSC-3 (as negative control) and HSC3M3/mbGluc cells. (e) A standard curve of Gluc activities. Culture media were prepared at 48 h after the medium change. (f) Relative Gluc activities of MEV and T-MEV. HSC3M3/mbGluc cells were transfected with control siRNA or si-CDC37/HSP90α/β for 24 h and then culture media were replaced with fresh ones. Gluc activities in the culture supernatants were measured at 6, 24 and 48 h after the medium changes. Values were normalized with the number of cells. n = 3.

**Triple depletion of CDC37/HSP90α/HSP90β attenuated cancer EV-driven malignancy events**

We next examined the effects of MEV and T-MEV on properties associated with processes involved in malignant progression, including the initiation of EMT in normal epithelial cells, advanced migration, invasion and tumorigenesis of oral cancer cells. MEV treatment of epithelial RT7 cells significantly increased the number of spindle-shaped cells compared to the PBS-treated control, whereas the EMT-initiating properties of MEV were significantly reduced by triple chaperone depletion (Figure 5a,b; Fig. S13). To confirm the alteration of EMT at the level of protein markers, we performed western blot analysis. Claudin-1 and E-cadherin were markedly reduced by MEV treatment of the epithelial cells compared to the PBS-treatment control, whereas triple chaperone depletion prevented the reduction in
claudin-1 and E-cadherin (Figure 5c; top and second raw blot; Fig. S14). Consistent with the reduced epithelial properties, a representative mesenchymal marker protein, vimentin was increased by the MEV treatment (Figure 5c; third raw blot). Meanwhile, Snail, a protein whose stability is important for the establishment of the EMT phenotype was increased by the MEV treatment, although also increased by T-MEV treatment (Figure 5c; fourth raw blot). β-catenin, whose activity is also important in the induction of EMT, was also increased by the MEV treatment of the epithelial cells (Figure 5c; bottom second blot). Triple chaperone depletion inhibited MEV-triggered increases in vimentin and β-catenin. Therefore, these data indicate that: (i) metastatic oral cancer-derived MEV was a potent inducer of EMT in epithelial cells and (ii) triple chaperone depletion effectively reduced EMT-initiating activity of metastatic EVs.

We next hypothesized that the EMT-inducing activity of MEV could potentially lead to augmented migration, invasion, and tumorigenesis of oral cancer cells. MEV promoted migration of HSC-3 cells as demonstrated by the scratch wound healing assay and by the chamber-well migration assay (Figure 5d–i). The depletion of the chaperone trio inhibited the MEV-driven migration of oral cancer cells (Figure 5d–g, MEV vs. T-MEV). MEV also promoted oral cancer cells to invade through matrices, whereas triple chaperone depletion attenuated the MEV-driven invasion (Figure 5h,i).

These data indicate that MEV initiates EMT in oral epithelial cells, an event attenuated by triple chaperone depletion. Additionally, MEV enhanced migration and invasion of oral cancer cells, events inhibited by triple chaperone depletion.

**Triple depletion of CDC37/HSP90α/HSP90β attenuated cancer EV-driven tumorsphere formation**

We have originally developed a 3D culture system for the evaluation of in vitro tumorigenesis with enhanced expression of cell adhesion molecules such as E-cadherin and CD326/EpCAM and cancer stem cell markers [13]. Next, we determined whether MEV could promote in vitro tumorigenesis and asked if depletion of the chaperone trio could cancel the MEV-driven tumorsphere formation. As TGFβ-pro-migratory activity can promote intercellular attachment leading to sphere formation [62], we used TGFβ-
promoting tumorsphere formation as a positive control. Tumorsphere formation by HSC-3 cells was significantly enhanced by MEV treatment (50 μg/mL) and by TGFβ treatment (5 ng/mL) compared to the PBS-treated control (Figure 6a,b; Fig. S15). Triple chaperone depletion significantly lowered the tumorsphere forming potential of MEV (Figure 6a,b; MEV vs. T-MEV). Moreover, T-MEV significantly inhibited tumorsphere formation compared to the control. The number of tumorspheres was significantly less in the T-MEV group than that in the MEV group (Figure 6c).

Some aspects of tumorigenesis, as well as tumorsphere formation, may require intercellular adhesion by CD326/EpCAM and E-cadherin and tight junctions formed by claudins [13,63,64]. Moreover, MEV tended to be enriched with CD326, as indicated in Figure 1. We therefore next asked whether the addition of MEV, T-MEV or TGFβ could alter CD326, E-cadherin, β-catenin and claudin-1 in tumorspheres. The addition of MEV or TGFβ stimulation increased levels of CD326, E-cadherin, β-catenin and claudin-1 in tumorspheres, while T-MEV tended to show lesser effects (Figure 6d, Fig. S16). Consistently, co-expression correlation of CD326/EpCAM and tetraspanin CD9 was found in HNSCC clinical cases with Spearman’s correlation score 0.51 \( (p = 1.43e^{-33}) \), Pearson’s correlation score 0.50 \( (p = 1.49e^{-32}) \), and a regression line \( (y = 0.99x\pm3.91) \) (Figure 6e), suggesting that CD326/EpCAM-related tumour-initiating activity could be involved in tetraspanins-bearing EV transmission.

These findings indicate that metastatic oral cancer-derived EVs increase cancer malignancy by promoting EMT, migration, invasion and tumorigenesis of oral cancer cells, whereas the siRNA-mediated triple depletion of CDC37/HSP90α/β could inhibit the MEV-driven oral cancer malignancy progression.

**HSP90α is dominantly expressed in cancer cells, while HSP90β is accumulated in tumour-associated macrophages in metastatic oral cancer**

To examine the expression and tissue localization of HSP90α and HSP90β in the tumour microenvironment, we next performed immunohistochemistry (IHC) on tumour specimens derived from patients.

![Figure 6. Metastatic EVs promote tumorsphere formation, a property diminished by triple chaperone knockdown. (a–d) In vitro tumorigenesis assay in the three-dimensional (3D) culture system. HSC-3 cells were treated with MEX (50 μg/mL), T-MEX (50 μg/mL), TGFβ (5 ng/mL) or PBS in nano-culture plates and then (a–c) tumorsphere formation and (d) protein expression levels were examined. (a) Representative photomicrographs of tumorspheres. Scale bars, 100 μm. (b) Column scatter plotting showing tumorsphere size. The size of the top 300 tumorspheres was measured in each group using ArrayScan HCS System. The horizontal lines indicate mean ± SD analysed by ANOVA Turkey’s multiple comparisons test. (c) The number of tumorspheres altered by MEX or T-MEX. Tumorspheres larger than 200 mm² were counted. n = 3, \( P = 0.0201 \). (d) Western blotting showing CD326/EpCAM, E-cadherin, β-catenin, claudin-1 and β-actin. The cell lysates were prepared from the tumorspheres. (e) Scatter plot showing co-expression correlation between CD326/EpCAM and CD9 in head and neck squamous cell carcinoma (HNSCC). A regression line was shown in red. Data were represented as log2. The data set of HNSCC with 523 patient-derived 523 samples (TCGA, Pan-Cancer Atlas) was analysed.](image-url)
suffering from stage IV (with metastasis) vs. stage I (without metastasis) oral squamous cell carcinoma. The HSP90α-positive cancer cell rate in the stage IV group was significantly higher than that in stage I (Figure 7a,b; Fig. S17). HSP90α-positive cells were also found in the stroma, although the levels were not significantly different between stage I and stage IV (Figure 7c). In contrast, the HSP90β-positive cancer cell rate in the stage I group was significantly higher than that in stage IV (Figure 7a,d). However, the HSP90β-positive stromal cell rate in stage IV oral cancer group was significantly higher than that in stage I (Figure 7a,e; Fig. S17). Additionally, we found that HSP90β-positive round-shaped cells and dendritic cells were infiltrating into tumours in stage IV oral cancer and were morphologically reminiscent of macrophages (Figure 7f, arrowheads).

These data suggested that HSP90 abundantly released by cancer cells could be taken TAM.

**Figure 7.** Metastatic oral cancer-derived MEVs induced macrophages M2 polarization. (a–f) Immunohistochemistry (IHC) of oral cancer patient-derived specimens. (a) Representative IHC showing HSP90α and HSP90β in stage I vs. stage IV oral cancers. Tu, tumour. St, stroma. — borders between tumour and stroma. (b–e) Rate of (b,c) HSP90α+ or (d,e) HSP90β+ cancer cells or stromal cells. The rates were calculated by counting immuno-positive cells per total cell number in each random field in (b,d) tumour areas or (c,e) 100 mm² stromal areas. Five random fields each in 8 oral cancer cases. N = 40. (f) IHC for HSP90β in stage I vs. stage IV oral cancer. Arrowheads, HSP90β-positive infiltrating tumour-associated macrophages (TAM). (g–j) Macrophage M2 polarity was altered by MEV and T-MEV. THP-1 cells were stimulated with PMA for the differentiation to macrophages and then treated with MEV, T-MEV (25 μg/mL) or PBS. (g) Representative images of THP-1 cells treated with or without PMA for 24 h. (h) Western blotting of extracellular and intracellular MMP-9 in THP-1 cells with or without PMA treatment. (i,j) Immunocytochemistry of macrophage markers with or without MEV or T-MEV. (i) Rate of CD206/CD68 double-positive M2-like macrophages. N = 9. (j) Representative staining images of CD206 (green) and CD68 (red). Blue, DAPI. Scale bars, 100 μm.
Metastatic EVs induce macrophages M2 polarization

Next, we asked whether macrophage M2 polarization could be altered by metastatic oral cancer-derived MEVs. As it has been shown that pro-tumorigenic metalloproteinase MMP9 was produced by M2 macrophages [65], we queried whether PMA and MEV could alter the MMP9 levels and release by macrophages. The monocytic cell line THP-1 was first differentiated to macrophage-like cells by stimulation with the phorbol ester PMA before EV treatment. THP-1 cells were morphologically monocyctic and non-adherent to tissue culture plates without PMA stimulation while the differentiated macrophage-like THP-1 cells adhered to tissue culture plates after the PMA treatment (Figure 7h; Fig. S18). Moreover, MMP9 was detectable in the PMA-treated THP-1, although not detectable without PMA treatment (Figure 7h). MMP9 secretion by THP-1-derived macrophages was enhanced by the MEV treatment, compared to PBS-treated control cells. Triple chaperone targeting of HSC-3-M3 reduced the MEV-driven MMP9 production by the macrophage-like cells (Fig. S19). The treatment with MEV tended to increase HSP90β in the macrophage-like cells, while T-MEX treatment showed a lesser effect.

To query whether the exposure to MEV could alter macrophage polarity, we next examined the expression of CD206, an M2 polarity marker, and CD68, a general macrophage marker. CD206/CD68 double-positive macrophages were significantly increased by the MEV treatment compared to PBS-treated control cells (Figure 7i,j; Fig. S20). Triple depletion of CDC37/HSP90α/β in HSC-3-M3 reduced the MEV-driven macrophage M2 polarization (Figure 7i,j; MEV vs. T-MEV).

These data show that metastatic oral cancer-derived EVs induce macrophage M2 polarization, a phenotype inhibited by triple depletion of CDC37/HSP90α/β/HSP90β. In addition, MEV-derived HSP90β could accumulate in macrophages and was involved in the M2 polarization.

Triple depletion of CDC37/HSP90α/HSP90β lowered EV transmission potentials

Next, we compared the transmission potentials of MEV and T-MEV to recipient cells. We have established and tested two methods of the EV labelling: (i) labelling EVs with red-fluorescent sphingolipid [845] and (ii) establishment of stable cells that produced membrane-bound palmitoylation signal-linked GFP or tdTomato red-fluorescent proteins [46]. Using the first method, we found that the transmission potential of T-MEV was significantly lower than that of MEV at 1.5 and 3 h after the EV addition to HSC-3 cells, although it was not significant at 6 and 12 h, indicating that there was a time-dependent reduction of the rate of transmission of EVs (Figure 8a,b).

A previous study had reported that GFP, as well as tdTomato RFP, fused with protein palmitoylation signal (designated palmtdTomato and palmGFP, respectively), were associated with the EV membrane, thus being released from producer cells into the culture supernatant [46,47]. To monitor the transmission of EVs, we established palmtdTomato-expressed HSC-3-M3 cells (designated HSC3M3/palmT), palmGFP-expressed HSC-3-M3 cells (designated HSC3M3/palmG), palmGFP-expressed HSC-3 cells (designated HSC3/palmG) and palmGFP-expressed THP-1 cells (designated THP1/palmG) (Figure 8c,d; Fig. S21). We collected EVs (palmT-MEV) from the culture supernatant of HSC3M3/palmT cells (Figure 8e). We then confirmed that the palmT-MEV were produced from HSC3M3/palmT cells and then being transmissive into HSC3M3/palmG cells, under CLSM (Figure 8f; Fig. S22a,b). Dose-dependent transmission of EVs was found in palmt-labelled MEV and T-MEV (Figure 8g). Triple targeting of CDC37/HSP90α/β significantly lowered the transmission of the palmt-labelled MEV into the recipient HSC3/palmG cells at 1, 3, and 6 h after the addition of the EVs (MEV vs. T-MEV) (Figure 8g,h; Fig. S22 c). To monitor the transmission of palmT-MEV into macrophages, THP1/palmG cells were differentiated into macrophage-like cells with PMA. Triple targeting of CDC37/HSP90α/β significantly lowered the uptake of the palmT-MEV by macrophages (Figure 8i,j; Fig. S22d). T-MEV uptake by macrophages was significantly lower than MEV and this lasted at least 24 h after the addition of EVs (Fig. S22e).

Thus, triple depletion of CDC37/HSP90α/HSP90β in metastatic oral cancer cells inhibited cancer vesicular transmission to recipient cells such as macrophages.

Discussion

Our data indicate the potency of metastatic tumour-derived EVs in changing the tumour microenvironment into a more pro-malignant state. We demonstrate that oral cancer-derived EVs possess the potential to initiate epithelial cell transformation – EMT, to promote the tumorigenic, migratory and invasive abilities of oral cancer cells and to polarize macrophages into an M2 phenotype. To potentially target these pro-malignant events, our data, for the first time, indicate the validity of triple depletion of the interacting CDC37/HSP90α/HSP90β complex (Figure 9, graphical abstract). siRNA-mediated triple depletion of...
CDC37/HSP90α/β significantly diminished the pro-malignant activities of oral cancer cells and MEVs. Although earlier studies had shown that intracellular HSP90 promotes cancer progression, indicating its targeting by small molecule inhibitors in clinical trials, we have uncovered novel roles for the co-chaperone CDC37 in cancer [10,14,28–30,44,55]. Notably, our data indicate that individual depletion of either HSP90α, HSP90β or CDC37 triggers simultaneous increases in the other chaperones. This observed compensatory response within the CDC37/HSP90 system was the rationale behind our original approach of depleting the three chaperones. Indeed, our data indicated that cancer-initiation and EMT markers were attenuated by the triple chaperone depletion more profoundly than double depletion. Consistently, our recent study showed that triple depletion of the chaperone trio inhibited tumorigenesis of prostate cancer cells in vivo [10]. As a potential mechanism, a recent study showed that directional cell movement through tissues is controlled by EV secretion [11,66]. Consistently, our data indicate that HSP90-high oral cancer-EVs promote migration-dependent tumorigenesis of cancer cells; triple chaperone depletion significantly diminished the pro-migratory activities of EVs. Thus, our studies could offer a potential solution to the pro-migratory and pro-tumorigenic activities of cancer EVs.

Figure 8. Triple knockdown of CDC37/HSP90α/HSP90β attenuates EV transmission potential into recipient macrophages and cancer cells. (a,b) Transmission of MEV and T-MEV into recipient HSC-3 cells. MEV was prepared from the culture supernatant of HSC-3-M3 transfected with si-Ctrl. T-MEV was prepared from the culture supernatant of HSC-3-M3 transfected with si-CDC37/90α/β. MEV and T-MEV were labelled with red-fluorescent ceramide and added to the culture media of HSC-3 cells. Cells were fixed at the indicated incubation period and analysed under fluorescent microscopy. (a) Representative images of vesicular transmission. Scale bars, 50 μm. Blue, DAPI staining. (b) The rate of EV transmission per total cells. N = 3. (c–j) Monitoring EVs labelled with membrane-bound palmitoylation (palm) signal-fused fluorescent proteins. (c) A scheme of the concept of fluorescent EV transmission. (d) Representative fluorescent images of HSC3-M3/palmT, HSC3-M3/palmM, HSC3/palmM and THP1/palmM cells. THP1/palmM was stimulated with PMA. Scale bars, 100 μm. (e) Representative TEM images of MEV released by HSC3M3/palmT cells. Scale bars, 200 nm. (f) Confocal laser scanning microscopy of HSC3/palmG cells treated with or without palmT-MEV. MEV (red) were prepared from culture media of HSC3 M3/palmT cells and added to the culture media of HSC3/palmG cells (green). Blue, DAPI staining. Scale bars, 20 μm. (g–j) MEV transmission rate into (g,h) HSC3/palmM cells or (i,j) THP1/palmM macrophages. For macrophage differentiation, THP1/palmM cells were stimulated with PMA. (g–i) Column scatters plotting of MEV transmission. The values indicate palmT fluorescence intensity per cell at 1 h after the addition of MEV or T-MEV. The upper end of each column indicates mean. (h,j) Transmission efficiencies of MEV vs. T-MEV into (h) HSC3/palmG cells and (j) THP1/palmM-derived macrophages. n = 3.
Our studies also, for the first time, indicate a potent role of HSP90-rich EVs in trans-cellular communication in the tumour microenvironment. It has been shown that cancer cell-derived EVs induce macrophage M2 polarity in breast cancer \[67\], colon cancer \[37\], pancreatic cancer \[38\], ovarian cancer \[68\], brain cancer \[69\], and head and neck cancer \[42\]. It was also reported that TAM showed an M2-type polarity in oral cancer and the number of such infiltrating TAM was correlated with poor prognosis \[70\]. Our studies were consistent with these reports, although, in oral cancer patient-derived tumours, we found that HSP90β- positive TAMs were profoundly associated with and infiltrating into the tumours. Distinctively, HSP90α might be processed during phagocytosis and antigen presentation, as HSPs play key roles in capturing tumour antigens and permitting their uptake and processing by antigen-presenting cells prior to activation of cytotoxic lymphocytes \[17,71–74\]. Relevantly, it has been shown that complexes of antigenic peptides with HSP90, calreticulin, and HSP70 were taken up by macrophages and dendritic cells and re-presented by MHC class I molecules \[73,75\]. Importantly, HSP90 mediates efficient antigen cross-presentation through scavenger receptors such as SCARF1 and LOX-1 \[76,77\]. Moreover, circulating EVs containing HSP90 were demonstrated to mediate the activation of macrophages and Kuffer cells in alcoholic liver disease \[78\]. Our current study indicated that loss of HSP90α/β significantly inhibited EV uptake by macrophages. Thus, it is conceivable that HSP90 is crucial for EV uptake, activation and M2-type polarization of macrophages. Our findings support one of our conclusions, namely that metastatic oral cancer releases HSP90-rich EVs leading to polarization of macrophages to an M2 phenotype, while triple chaperone knockdown is effective in inhibiting EV uptake by TAM and their M2 polarization.

Our studies also suggest that tetraspanins (CD9 and CD63) might be crucial mediators for cell-cell communication in tumour progression and programming of the microenvironment. It has been shown that tetraspanins are crucial for intercellular communications required for cancer progression \[64,79,80\], while CD9 and CD63 are exosome markers and potentially contained in other EV types \[1\]. In our study, the total protein concentrations of the EV fractions were not different between the triple knockdown versus the control, while EVs that contained HSP90, CD9, CD63 and mbGluc appeared to be reduced by the triple

---

**Figure 9.** Graphical abstract. (a) Metastatic oral cancer cells secreted HSP90-high EVs transmitting to recipient cells. Metastatic oral cancer-EVs initiated EMT in normal epithelial cells and promoted migration, invasion, and tumorigenesis in oral cancer cells and M2-like polarity in tumour-associated macrophages. (b) The siRNAs-mediated triple silencing of CDC37/HSP90α/HSP90β diminished EMT markers in oral cancer cells. The HSP90-depleted EVs-reduced activities for transmission and pro-malignancy in recipient cells.
chaperone knockdown, also suggesting that the number of EVs (or exosomes) that contained HSP90, CD9 and CD63 might be reduced by this targeting, while the other components must be increased instead. Such a loss of tumour-promoting EVs can be a mechanism by which triple chaperone knockdown effectively inhibits protumorigenic events and EV uptake by macrophages.

In conclusion, we have demonstrated that the siRNA-mediated triple silencing of CDC37/HSP90a/ HSP90β could potentially lead to a novel therapeutic strategy for attenuating cancer EV-driven macrophage M2 polarization, EMT, migration, invasion and tumorigenesis. We also unveiled the novel finding that the triple chaperone depletion weakens the EV transmission activity required for pro-tumorigenic cell-cell communication in the tumour microenvironment.

Acknowledgments

This paper is dedicated to the memory of one of our mentors, Professor Ken-ichi Kozaki, who passed away on 29 May 2016. The authors thank Haruo Urata for the operation of TEM, Tomonari Kasai and Masaharu Seno for particle size analysis using ELS-8000, Kazuko Kobayashi for the operation of Zetasizer, Eriko Aoyama for maintenance of HCS analyzer. The authors thank Manabu Itoh and Kazuya Arai at JSR for technical advice in NCP. The authors thank Keisuke Nakano for illuminating discussion and encouraging support.

Funding

This work was supported by JSPS KAKENHI, grant numbers [17K11642 (T.E.), 17K11643 (C.S., T.E.), 17K11669 (K.Oh., T.E.), 19K24072 (K.On.), 16K1722-JM (T.E., H.N.), 19K10288-JM (H.N.), 18K09789-KN (H.N., T.E.), JP16K11441 (H.N.), JP20H03888 (H.N., T.E.), 19H03817 (M.T., T.E.), 19H04051 (H.O., T.E.) and 20K09904 (C.S., T.E., K.Ok.)], Ryobi Telen Memorial Foundation Grant (K.Ok., C.S., T.E.), Suzuken Memorial Foundation Grant (T.E.) and NIH Grant CA176326-05 (SKC).

Author contributions

TE, KOn and SKC conceptualized and administrated the study. TE acquired funding. HN, AS, KK, MT, KOk, HO, SI and TE prepared resources. TE, CS, MTT, HK, KOn, KK, HO and KK devised methodology. KOn, HK, MTT, EAT, YL, YO, CS and MWO performed the experimentation. KOn, HK, TE, MTT and CS curated, validated and visualized data. TE, CS, KOk, HO and KK supervised. TE, KOn and HK wrote the original draft. TE and SKC reviewed and edited, and revised the manuscript. All authors reviewed the manuscript.

Competing financial interests

The authors declare no competing financial interests.

ORCID

Takanori Eguchi http://orcid.org/0000-0002-3297-6126

References

[1] Thery C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the international society for extracellular vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7(1):1535750.
[2] Colombo M, Raposo G, Thery C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014;30:255–289.
[3] van Niel G, D’Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018 Apr;19(4):213–228.
[4] Seyama M, Yoshida K, Yoshida K, et al. Outer membrane vesicles of Porphyromonas gingivalis attenuate insulin sensitivity by delivering gingipains to the liver. Biochim Biophys Acta Mol Basis Dis. 2020 Feb 20:1866(6):1–12.
[5] Okusha Y, Eguchi T, Tran MT, et al. Extracellular vesicles enriched with moonlighting metalloproteinase are highly transmissive, pro-tumorigenic, and trans-activates cellular communication network factor (CCN2/CTGF); CRISPR against cancer. Cancers (Basel). 2020;12(4):1–27.
[6] Hoshino A, Costa-Silva B, Shen TL, et al. Tumour exosome integrins determine organotropic metastasis. Nature. 2015 Nov 19;527(7578):329–335.
[7] Franzen CA, Blackwell RH, Todorovic V, et al. Urothelial cells undergo epithelial-to-mesenchymal transition after exposure to muscle invasive bladder cancer exosomes. Oncogenesis. 2015 Aug;17(4):e163.
[8] Fujiiwara T, Eguchi T, Sagawa C, et al. Carcinogenic epithelial-mesenchymal transition initiated by oral cancer exosomes is inhibited by anti-EGFR antibody cetuximab. Oral Oncol. 2018;86:251–257.
[9] Clayton A, Turkes A, Navabi H, et al. Induction of heat shock proteins in B-cell exosomes. J Cell Sci. 2005 Aug 15;118(Pt 16):3631–3638.
[10] Eguchi T, Sagawa C, Ono K, et al. Cell stress induced stromal release including damaged membrane vesicles and extracellular HSP90 by prostate cancer cells. Cells. 2020;9(3):1–24.
[11] Eguchi T, Ono K, Kawata K. Regulatory roles of HSP90-Rich extracellular vesicles. In: Asea AAA and Kaur P, editors. Heat shock protein 90 in human diseases and disorders. Heat shock proteins. Vol. 19. Cham, Switzerland: Springer Nature; 2019. p. 3–17.
[12] Ono K, Eguchi T, Sagawa C, et al. HSP-enriched properties of extracellular vesicles involve survival of metastatic oral cancer cells. J Cell Biochem. 2018 Sep;119(9):7350–7373.
[13] Eguchi T, Sogawa C, Okusha Y, et al. Organoids with cancer stem cell-like properties secrete exosomes and HSP90 in a 3D nanoenvironment. Plos One. 2018 Feb 7;13(2):e0191109.

[14] Calderwood SK. Molecular co-chaperones: tumor growth and cancer treatment. Scientifica (Cairo). 2013;2013:217513.

[15] Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med. 2002;8(4 Suppl):555–61.

[16] Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer. 2005 Oct;5(10):761–772.

[17] Taha EA, Ono K, Eguchi T. Roles of extracellular HSPs as biomarkers in immune surveillance and immune evasion [Review]. Int J Mol Sci. 2019 Sep 17;20(18):1–32.

[18] Eustace BK, Sakurai T, Stewart JK, et al. Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat Cell Biol. 2004 6;Jun(6):507–514.

[19] Nolan KD, Franco OE, Hance MW, et al. Tumor-secreted Hsp90 subverts polycomb function to drive prostate tumor growth and invasion. J Biol Chem. 2015 Mar 27;290(13):8271–8282.

[20] Hance MW, Dole K, Gopal U, et al. Secreted Hsp90 is a novel regulator of the epithelial to mesenchymal transition (EMT) in prostate cancer. J Biol Chem. 2012 Nov 02;287(45):37732–37744.

[21] Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009 Jun;28(1–2):15–33.

[22] Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008 May 16;133(4):704–715.

[23] Fujiwara T, Eguchi T, Sogawa C, et al. Anti-EGFR antibody cetuximab is secreted by oral squamous cell carcinoma and alters EGF-driven mesenchymal transition. Biochem Biophys Res Commun. 2018;503(3):1267–1272. 2018 Available online 13 July.

[24] Eguchi T, Taha EA, Calderwood SK, et al. A novel model of cancer drug resistance: oncosomal release of cytotoxic and antibody-based drugs [Review]. Biology (Basel). 2020 Mar 5;9(3):1–22.

[25] Zheng X, Carstens JL, Kim J, et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature. 2015 Nov 26;527(7579):525–530.

[26] Nieto MA, Huang RY, Jackson RA, et al. Emt: 2016. Cell. 2016 Jun 30;166(1):21–45.

[27] Blackwell RH, Foreman KE, Gupta GN. The role of cancer-derived exosomes in tumorigenesis & epithelial-to-mesenchymal transition. Cancers (Basel). 2017. 10. 9 (8):Aug.

[28] Gray PJ, Prince T, Cheng J, et al. Targeting the oncoprotein and kinase chaperone CDC37. Nat Rev Cancer. 2008;8:491–495.

[29] Gray PJ Jr., Stevenson MA, Calderwood SK. Targeting Cdc37 inhibits multiple signaling pathways and induces growth arrest in prostate cancer cells. Cancer Res. 2007 Dec 15;67(24):11942–11950.

[30] Calderwood SK. Cdc37 as a co-chaperone to Hsp90. Subcell Biochem. 2015;78:103–112.

[31] Kimura Y, Rutherford SL, Miyata Y, et al. Cdc37 is a molecular chaperone with specific functions in signal transduction. Genes Dev. 1997;11:1775–1785.

[32] Roe SM, Ali MMU, Meyer P, et al. The mechanism of Hsp90 regulation by the protein kinase-specific co-chaperone p50 cdc37. Cell. 2004;116:87–98.

[33] Chua HL, Bhat-Nakshatri P, Clare SE, et al. NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene. 2007 Feb 01;26(5):711–724.

[34] Wu Y, Deng J, Rychahou PG, et al. Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. Cancer Cell. 2009 May 05;15(5):416–428.

[35] Li CW, Xia W, Huo L, et al. Epithelial-mesenchymal transition induced by TNF-alpha requires NF-kappaB-mediated transcriptional upregulation of Twist1. Cancer Res. 2012 Mar 01;72(5):1290–1300.

[36] Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol. 2011 Oct 14;11(11):723–737.

[37] Lan J, Sun L, Xu F, et al. M2 macrophage-derived exosomes promote cell migration and invasion in colon cancer. Cancer Res. 2019 Jan 1;79(1):146–158.

[38] Wang X, Luo G, Zhang K, et al. Hypoxic tumor-derived exosomal miR-301a mediates M2 macrophage polarization via PTEN/P13Kgamma to promote pancreatic cancer metastasis. Cancer Res. 2018 Aug 15;78(16):4586–4598.

[39] Zheng P, Chen L, Yuan X, et al. Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells. J Exp Clin Cancer Res. 2017 Apr 13;36(1):53.

[40] Taha EA, Lu Y, Eguchi T. Exosomes—The little thing that matter the most in tumor immunology and microenvironment. In: kagiya T, editor. Exosomes and microvesicles: role in disease and clinical applications. Hauppauge, New York: Nova Science Publishers;2020.

[41] Wang F, Li B, Wei Y, et al. Tumor-derived exosomes induce PD1(+) macrophage population in human gastric cancer that promotes disease progression. Oncogenesis. 2018 May 25;7(5):41.

[42] Pirila E, Vayrynen O, Sundquist E, et al. Macrophages modulate migration and invasion of human tongue squamous cell carcinoma. PLoS One. 2015;10(3):e0120895.

[43] Ono K, Eguchi T, Sogawa C, et al. HSP-enriched properties of extracellular vesicles involve survival of metastatic oral cancer cells. J Cell Biochem. 2018 May 16;119(9):7350–7362.

[44] Eguchi T, Prince TL, Tran MT, et al. MZF1 and SCAND1 Reciprocally Regulate CDC37 Gene Expression in Prostate Cancer. Cancers (Basel). 2019 Jun 8;11(6):1–15.

[45] Namba Y, Sogawa C, Okusha Y, et al. Depletion of lipid efflux pump ABCG1 triggers the intracellular accumulation of extracellular vesicles and reduces aggregation and tumorigenesis of metastatic cancer cells. Front Oncol. 2018;8(376):1–16.
[46] Lai CP, Kim EY, Badr CE, et al. Knockout of MMP3 weakens solid tumor organoids and cancer extracellular vesicles. Cancers. in press.

[47] Lai CP, Kim EY, Badr CE, et al. Visualization and tracking of tumour extracellular vesicle delivery and RNA translation using multiplexed reporters. Nat Commun. 2015 May;13(6):7029.

[48] Lai CP, Mardini O, Ericsson M, et al. Dynamic biodistribution of extracellular vesicles in vivo using a multimodal imaging reporter. ACS Nano. 2014 Jan 28;8(1):483–494.

[49] Eguchi T, Kubota S, Kawata K, et al. Novel transcription-factor-like function of human matrix metalloproteinase 3 regulating the CTGF/CCN2 gene. Mol Cell Biol. 2008 Apr;28(7):2391–2413.

[50] Arai K, Eguchi T, Rahman MM, et al. A novel high-throughput 3D screening system for EMT inhibitors: a pilot screening discovered the EMT inhibitory activity of CDK2 inhibitor SU9516. PLoS One. 2016;11(9):e0162394.

[51] Sogawa C, Eguchi T, Tran MT, et al. Antiparkinson drug benzotropine suppresses tumor growth, circulating tumor cells, and metastasis by acting on SLC6A3/DA and reducing STAT3. Cancer (Basel). 2020;12(2):1–22.

[52] Sogawa C, Eguchi T, Okusha Y, et al. A reporter system evaluates tumorigenesis, metastasis, beta-catenin/MMP regulation, and druggability. Tissue Eng Part A. 2019 Feb 8;25(19–20):1413–1425.

[53] Yoshida S, Kawai H, Eguchi T, et al. Tumor angiogenic inhibition triggered necrosis (TAITN) in oral cancer. Cells. 2019 Jul 22;8(7):1–15.

[54] Okusha Y, Eguchi T, Sogawa C, et al. The intranuclear PEX domain of MMP involves proliferation, migration, and metastasis of aggressive adenocarcinoma cells. J Cell Biochem. 2018 Sep;119(9):7363–7376.

[55] Eguchi T, Sogawa C, Ono K, et al. CDC37 and HSP90 are essential for stressosome release and tumor progression in resistant prostate cancer. 11 February 2020 by MDPI (Preprints). doi:10.20944/preprints202002.0148.v1.

[56] Litvinov SV, Velders MP, Bakker HA, et al. Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol. 1994 Apr;125(2):437–446.

[57] Munz M, Baeuerle PA, Gires O. The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res. 2009 Jul 15;69(14):5627–5629.

[58] Zona L, Tawar RG, Zeisel MB, et al. CD81-receptor associations--impact for hepatitis C virus entry and antiviral therapies. Viruses. 2014 Feb 18;6(2):875–892.

[59] van Niel G, Charrin S, Simoes S, et al. The tetraspanin CD63 regulates ESCRT-independent and -dependent endosomal sorting during melanogenesis. Dev Cell. 2011 Oct 18;21(4):708–721.

[60] Pols MS, Klumperman J. Trafficking and function of the tetraspanin CD63. Exp Cell Res. 2009 May 15;315(9):1584–1592.

[61] Li W, Li Y, Guan S, et al. Extracellular heat shock protein-90alpha: linking hypoxia to skin cell motility and wound healing. Embo J. 2007 Mar 7;26(5):1221–1233.

[62] de la Mare JA, Jurgens T, Edkins AL. Extracellular Hsp90 and TGFbeta regulate adhesion, migration and anchorage independent growth in a paired colon cancer cell line model. BMC Cancer. 2017 Mar 16;17(1):202.

[63] Capaldo CT, Nusrat A. Claudin switching: physiological plasticity of the Tight Junction. Semin Cell Dev Biol. 2015 Jun;42:22–29.

[64] Le Naour F, Zoller M. The tumor antigen EpCAM: tetraspanins and the tight junction protein claudin-7, new partners, new functions. Front Biosci. 2008 May 1;13:5847–5865.

[65] Luo Y, Zhou H, Krueger J, et al. Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest. 2006 Aug;116(8):2132–2141.

[66] Sung BH, Ketova T, Hoshino D, et al. Directional cell movement through tissues is controlled by exosome secretion. Nat Commun. 2015 May;13(6):7164.

[67] Ham S, Lima LG, Chai EPZ, et al. Breast cancer-derived exosomes alter macrophage polarization via gp130/STAT3 Signaling. Front Immunol. 2018;9:871.

[68] Kanlikilic P, Bayraktar R, Denizli M, et al. Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer. EBioMedicine. 2018;38:100–112.

[69] de Vrij J, Maas SL, Kwappenberg KM, et al. Glioblastoma-derived extracellular vesicles modify the phenotype of monocytic cells. Int J Cancer. 2015 Oct 1;137(7):1630–1642.

[70] Fujii N, Shomori K, Shiomi T, et al. Cancer-associated fibroblasts and CD163-positive macrophages in oral squamous cell carcinoma: their clinicopathological and prognostic significance. J Oral Pathol Med. 2012 Jul;41(6):444–451.

[71] Calderwood SK, Gong J, Murshid A. Extracellular HSPs: the Complicated Roles of Extracellular HSPs in Immunity. Front Immunol. 2016;7:159.

[72] Murshid A, Gong J, Calderwood SK. Hsp90-peptide complexes stimulate antigen presentation through the class II pathway after binding scavenger receptor SREC-I. Immunobiology. 2014 Dec;219(12):924–931.

[73] Furuta K, Eguchi T. Roles of heat shock proteins on antigen presentation. In: Asea AA, Kaur P, editors. Heat shock proteins in cancer therapeutics. heat shock proteins. 2020, in press. Cham, Switzerland: Springer Nature.

[74] Udo H, Srivastava PK. Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90, and hsp70. J Immunol. 1994 Jun 1;152(11):5398–5403.

[75] Basu S, Binder RJ, Ramalingam T, et al. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity. 2001 Mar;14(3):303–313.

[76] Murshid A, Gong J, Calderwood SK. Heat shock protein 90 mediates efficient antigen cross presentation through the scavenger receptor expressed by endothelial cells-1. J Immunol. 2010 Sep 1;185(5):2903–2917.

[77] Murshid A, Borges TJ, Bonorino C, et al. Immunological outcomes mediated upon binding of heat shock proteins to scavenger receptors SCARF1 and LOX-1, and endocytosis by mononuclear phagocytes. Front Immunol. 2019;10:3035.
[78] Saha B, Momen-Heravi F, Furi I, et al. Extracellular vesicles from mice with alcoholic liver disease carry a distinct protein cargo and induce macrophage activation through heat shock protein 90. Hepatology. 2018 May;67(5):1986–2000.

[79] Hemler ME. Tetraspanin proteins promote multiple cancer stages. Nat Rev Cancer. 2014 Jan;14(1):49–60.

[80] Charrin S, Jouannet S, Boucheix C, et al. Tetraspanins at a glance. J Cell Sci. 2014 Sep 1;127(Pt 17):3641–3648.